Suppr超能文献

COVID-19 大流行对≥67 岁有糖尿病的 Medicare 按服务收费受益人的医疗支出的影响。

Impact of the COVID-19 Pandemic on Medical Expenditures Among Medicare Fee-for-Service Beneficiaries Aged ≥67 Years With Diabetes.

机构信息

Division of Diabetes Translation, Centers for Disease Control and Prevention, Atlanta, GA.

出版信息

Diabetes Care. 2024 Mar 1;47(3):452-459. doi: 10.2337/dc23-1679.

Abstract

OBJECTIVE

To compare total and out-of-pocket (OOP) medical expenditures between pre-COVID-19 (March 2019 to February 2020) and COVID-19 (March 2020 to February 2022) periods among Medicare beneficiaries with diabetes.

RESEARCH DESIGN AND METHODS

Data were from 100% Medicare fee-for-service claims. Diabetes was identified using ICD-10 codes. We calculated quarterly total and OOP medical expenditures at the population and per capita level in total and by service type. Per capita expenditures were calculated by dividing the population expenditure by the number of beneficiaries with diabetes in the same quarter. Changes in expenditures were calculated as the differences in the same quarters between the prepandemic and pandemic years.

RESULTS

Population total expenditure fell to $33.6 billion in the 1st quarter of the pandemic from $41.7 billion in the same prepandemic quarter; it then bounced back to $36.8 billion by the 4th quarter of the 2nd pandemic year. The per capita total expenditure fell to $5,356 in the 1st quarter of the pandemic from $6,500 in the same prepandemic quarter. It then increased to $6,096 by the 4th quarter of the 2nd pandemic year, surpassing the same quarter in the prepandemic year ($5,982). Both population and per capita OOP expenditures during the pandemic period were lower than the prepandemic period. Changes in per capita expenditure between the pre-COVID-19 and COVID-19 periods by service type varied.

CONCLUSIONS

COVID-19 had a significant impact on both total and per capita medical expenditures among Medicare beneficiaries with diabetes. The COVID-19 pandemic was associated with lower OOP expenditures.

摘要

目的

比较新冠疫情前(2019 年 3 月至 2020 年 2 月)和新冠疫情期间(2020 年 3 月至 2022 年 2 月)医疗保险受益人为糖尿病患者的总医疗支出和自付医疗支出(OOP)。

研究设计和方法

数据来自 100%的医疗保险按服务收费的索赔。使用 ICD-10 代码确定糖尿病。我们计算了人口和人均水平的季度总支出和 OOP 医疗支出,并按服务类型进行了分类。人均支出是通过将同一季度的人口支出除以糖尿病受益人数来计算的。支出变化是通过在大流行年和大流行前年份的同一季度之间的差异来计算的。

结果

疫情第 1 季度的人口总支出从大流行前同期的 417 亿美元降至 336 亿美元;然后在第 2 年大流行的第 4 季度反弹至 368 亿美元。疫情第 1 季度的人均总支出从大流行前同期的 6500 美元降至 5356 美元。然后在第 2 年大流行的第 4 季度增加到 6096 美元,超过了大流行前同期(5982 美元)。在疫情期间,人口和人均 OOP 支出均低于大流行前。按服务类型划分,COVID-19 期间人均支出的变化在大流行前和大流行期间有所不同。

结论

COVID-19 对医疗保险受益人为糖尿病患者的总支出和人均支出都产生了重大影响。新冠疫情与较低的 OOP 支出有关。

相似文献

本文引用的文献

7
Comparisons of Insulin Spending and Price Between Canada and the United States.加拿大与美国胰岛素支出及价格对比
Mayo Clin Proc. 2022 Mar;97(3):573-578. doi: 10.1016/j.mayocp.2021.11.028. Epub 2022 Feb 5.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验